José Tempero

Cannabinoid Treatment Significantly Reduces Fibromyalgia Pain And Improves Quality Of Life, New Tilray-Backed Study Finds
Tilray Medical, a division of Canadian cannabis giant Tilray Brands, Inc. (NASDAQ: TLRY) (TSX: TLRY) announced on Monday a new scientific publication supported by Tilray Medical titled, Treatment in Pain Management and Other Fibromyalgia-Associated Symptoms: A Case Series (TOMAS). The study, consisting of patients with an average age of 52 years, examines the real-world impact of cannabinoid treatments on patients with fibromyalgia (FM) under the guidance of healthcare providers. The study revealed improvements in pain levels, sleep quality, and overall well-being for patients with fibromyalgia.
90% Of Medical Marijuana Patients Over 50 Are Treating Chronic Pain And Arthritis, Finds New Tilray Study
Tilray Medical, a division of Tilray Brands, Inc. (NASDAQ: TLRY) (TSX: TLRY) announced on Tuesday its new scientific publication titled, Medical Cannabis for Patients Over Age 50: A Multi-Site, Prospective Study of Patterns of Use and Health Outcomes. The new research builds on a separate study done by the medical cannabis giant that found that Older patients comprise a growing subset of medical marijuana patients. That study found that patients with chronic pain (27.8%), arthritis (14.9%) and anxiety (9%) were the most numerous among those seeking cannabis to treat their primary illnesses. Pain was the most common primary symptom for which patients use medical cannabis, followed by anxiety and insomnia/sleep disorder, according to the study.The Medical Cannabis in Older Patients Study is a multi-site, prospective, observational study examining the real-world impact of medical use on patients over the age of 50 and under the guidance of a healthcare provider. It presented to the medical and scientific community the impact of medical cannabis on health outcomes. The main focus was on pain, sleep and quality of life.